InflaRx (NASDAQ:IFRX – Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totalling 250,600 shares, a growth of 281.4% from the July 15th total of 65,700 shares. Based on an average daily trading volume, of 128,800 shares, the days-to-cover ratio is presently 1.9 days.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of InflaRx in a research note on Monday, June 24th.
View Our Latest Report on InflaRx
InflaRx Stock Performance
Hedge Funds Weigh In On InflaRx
Hedge funds have recently modified their holdings of the company. Raymond James & Associates lifted its position in InflaRx by 7.9% during the fourth quarter. Raymond James & Associates now owns 175,279 shares of the company’s stock valued at $286,000 after buying an additional 12,873 shares during the period. Raymond James Financial Services Advisors Inc. grew its holdings in InflaRx by 18.2% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 317,859 shares of the company’s stock valued at $518,000 after purchasing an additional 48,944 shares during the period. Finally, Ikarian Capital LLC lifted its stake in shares of InflaRx by 2.4% during the 1st quarter. Ikarian Capital LLC now owns 704,987 shares of the company’s stock valued at $1,086,000 after buying an additional 16,383 shares in the last quarter. Hedge funds and other institutional investors own 42.39% of the company’s stock.
About InflaRx
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
See Also
- Five stocks we like better than InflaRx
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- How to Calculate Options Profits
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- What is the NASDAQ Stock Exchange?
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.